El Cytoxan se utiliza para tratar ciertos tipos de los siguientes canceres: linfoma, mieloma múltiple, leucemia, micosis fungoides, neuroblastoma, cáncer de ovario, cáncer ocular y cáncer de mama. Generalmente se utiliza junto con otros medicamentos. También puede utilizarse para tratar ciertos problemas renales (síndrome nefrótico) en niños. Más informaión »
Recibí mi encargo la semana pasada. Muchas gracias. ¡Voy a realizar pronto otro pedido! ¡! Mi mujer estuvo todavía más sorprendida que yo... Volví a ser un joven nuevamente. Gracias:)
- David
Nuestra página de facturación está certificada por:
Cyclophosphamide drug makes the bone marrow more tumor-friendly - News-Medical.net
Cyclophosphamide drug makes the bone marrow more tumor-friendlyNews-Medical.
Docs Need Primer on Long-Term Effects of Chemotherapy - Family Practice News Digital Network
Family Practice News Digital NetworkDocs Need Primer on Long-Term Effects of ChemotherapyFamily Practice News Digital NetworkOnly 6% of primary care physicians were able to identify the main long-term effects (LEs) of doxorubicin (Adriamycin), paclitaxel (Taxol), oxaliplatin (Eloxatin), and cyclophosphamide (Cytoxan), compared with 65% of oncologists surveyed.
Is Dose-Dense Therapy Effective Against DLBCL in the Era of Rituximab? - Cancer Network
Is Dose-Dense Therapy Effective Against DLBCL in the Era of Rituximab?Cancer NetworkIn their review article in this issue of ONCOLOGY, Nastoupil, Rose, and Flowers discuss the progress from the older chemotherapy regimen, CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), to immuno-chemotherapy.
Is There a Best Adjuvant Chemotherapy Regimen for Breast Cancer? - OncLive
OncLiveIs There a Best Adjuvant Chemotherapy Regimen for Breast Cancer?OncLiveCytotoxic therapy consisting of cyclophosphamide– methotrexate–5-fluorouracil (CMF)-based regimens showed a 24% reduction in breast cancer recurrence and 14% reduction in death, compared with placebo.
First cycle G-CSF for high-risk chemotherapy: Of Course! - Clinical Oncology News
Clinical Oncology NewsFirst cycle G-CSF for high-risk chemotherapy: Of Course!Clinical Oncology NewsDawn Hershman, MD, of Columbia University in New York City, recently published an article in the Journal of Clinical Oncology noting the rapid uptake of dose-dense AC-Taxol (doxorubicin and cyclophosphamide followed by paclitaxel [ddAC-T]).